Margaret M Swanberg1. 1. Department of Neurology, Walter Reed Army Medical Center, Washington, DC 20307, USA. Margaret.Swanberg@us.army.mil
Abstract
BACKGROUND: Frontotemporal dementia (FTD) is one of the more common presenile dementias. Unlike Alzheimer disease, there are no approved medications to treat this debilitating condition. OBJECTIVE: To report the response of memantine on the behavioral manifestations of FTD. DESIGN: Case series of 3 patients diagnosed with FTD and treated with memantine. RESULTS: All 3 patients showed an improvement in total Neuropsychiatric Inventory score with specific improvements in the subscale scores of apathy, agitation, and anxiety. Memantine was well tolerated in all patients. CONCLUSIONS: This small case series supports the notion that memantine may have a beneficial effect on the neuropsychiatric symptoms of FTD and should be further studied in a prospective clinical trial.
BACKGROUND: Frontotemporal dementia (FTD) is one of the more common presenile dementias. Unlike Alzheimer disease, there are no approved medications to treat this debilitating condition. OBJECTIVE: To report the response of memantine on the behavioral manifestations of FTD. DESIGN: Case series of 3 patients diagnosed with FTD and treated with memantine. RESULTS: All 3 patients showed an improvement in total Neuropsychiatric Inventory score with specific improvements in the subscale scores of apathy, agitation, and anxiety. Memantine was well tolerated in all patients. CONCLUSIONS: This small case series supports the notion that memantine may have a beneficial effect on the neuropsychiatric symptoms of FTD and should be further studied in a prospective clinical trial.
Authors: Adam L Boxer; David S Knopman; Daniel I Kaufer; Murray Grossman; Chiadi Onyike; Neill Graf-Radford; Mario Mendez; Diana Kerwin; Alan Lerner; Chuang-Kuo Wu; Mary Koestler; Jill Shapira; Kathryn Sullivan; Kristen Klepac; Kristine Lipowski; Jerin Ullah; Scott Fields; Joel H Kramer; Jennifer Merrilees; John Neuhaus; M Marsel Mesulam; Bruce L Miller Journal: Lancet Neurol Date: 2013-01-02 Impact factor: 44.182
Authors: Kyle B Womack; Ramon Diaz-Arrastia; Howard J Aizenstein; Steven E Arnold; Nancy R Barbas; Bradley F Boeve; Christopher M Clark; Charles S DeCarli; William J Jagust; James B Leverenz; Elaine R Peskind; R Scott Turner; Edward Y Zamrini; Judith L Heidebrink; James R Burke; Steven T DeKosky; Martin R Farlow; Matthew J Gabel; Roger Higdon; Claudia H Kawas; Robert A Koeppe; Anne M Lipton; Norman L Foster Journal: Arch Neurol Date: 2010-11-08